NCT06631430View on ClinicalTrials.gov

A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

June 12, 2025

Study Completion Date

June 12, 2025

Conditions
Healthy
Interventions
DRUG

BI 3810477

BI 3810477 formulation A

DRUG

BI 3810477

BI 3810477 formulation B

DRUG

Placebo

Placebo

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY